Association between statin use and all-cause mortality in cancer survivors, based on the Korean health insurance service between 2002 and 2015

Kim, Joungyoun; Choi, Eun‐A; Han, Ye-Eun; Lee, Jae-woo; Kim, Yeseul; Kim, Yonghwan; You, Hyo-Sun; Hyun, Hyeong-Jin; Kang, Hee-Taik

doi:10.1016/j.numecd.2019.11.002

Cited by 8 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…182,183 There is a benefit for CS from an all-cause mortality perspective as well as for decreasing cancer recurrence. [728][729][730] Several studies have demonstrated the therapeutic benefits of exercise during primary anticancer treatment, 731,732 and exercise is recommended during and after anticancer treatment. 11,733 For CS, 734 aerobic exercise results in improved survival.…”

Section: Metabolic Syndrome Lipid Abnormalities Diabetes Mellitus And...mentioning

confidence: 99%

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Lyon¹,

López‐Fernández²,

Couch³

et al. 2022

European Heart Journal

1,015

934

View full text Add to dashboard Cite

Coronary care unit CDK Cyclin-dependent kinase CHA 2 DS 2 -VASc Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, Stroke (2 points)-Vascular disease, Age 65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR Cardiac magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic risk assessment with clinical Perceptions and AwareneSS in real-life patients-Cancer Associated Thrombosis CPET Cardiopulmonary exercise testing CrCl Creatinine clearance CRF Cardiorespiratory fitness CRS Cytokine release syndrome CS Cancer survivors CT Computed tomography CTLA-4 Cytotoxic T lymphocyte-associated antigen-4 cTn Cardiac troponin CTRCD Cancer therapy-related cardiac dysfunction CTR-CVT Cancer therapy-related cardiovascular toxicity CV Cardiovascular CVD Cardiovascular disease CVRF Cardiovascular risk factorsData derived from a single randomized clinical trial or large non-randomized studies.Consensus of opinion of the experts and/or small studies, retrospective studies, registries.©ESC 2022 ESC Guidelines © ESC 2022This table refers to anthracycline equivalence dose using doxorubicin as a reference. Note that these isoequivalent doses are derived from paediatric CS. CS, cancer survivors; CV, cardiovascular.a Data for idarubicin are based upon an estimated anticancer efficacy ratio, not derived from cardiotoxicity data. The CV toxicity dose ratio provides the value that should be used to multiply the dose of the anthracycline of interest to convert to isoequivalent doses of doxorubicin; e.g. to convert 125 mg/m 2 of epirubicin to doxorubicin isoequivalent, multiply the dose by 0.8 (125 mg/m 2 × 0.8 = 100 mg/m 2 of doxorubicin).

show abstract

Section: Metabolic Syndrome Lipid Abnormalities Diabetes Mellitus And...mentioning

confidence: 99%

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Lyon¹,

López‐Fernández²,

Couch³

et al. 2022

European Heart Journal

1,015

934

View full text Add to dashboard Cite

show abstract

“…Recently, an increased number of studies have investigated via in vitro and in vivo experiments various combinatorial chemotherapy regimens with compounds from different classes, i.e., statins, curcuminoids, or isothiocyanate [20][21][22], as means to enhance the cytotoxic effect of conventional chemotherapeutic drugs. Among these classes, statins were the only ones that were tested in clinical trials and provided an improved therapeutic response due to their pleiotropic effects, i.e., antiproliferative, anti-inflammatory, and antioxidant [23][24][25]. Additionally, it was demonstrated that statin therapy has a cardioprotective effect on women with breast cancer who followed a therapy with anthracyclines by reducing the number of heart failure hospitalizations [26].…”

Section: Introductionmentioning

confidence: 99%

“…Among statins, simvastatin (SIM) represents a promising option for a potential association with DOX for two reasons. Firstly, SIM possesses a lipophilic character which was demonstrated to enhance its diffusion in cells, thus exerting a greater cytotoxic effect on cancerous cells [25], and, secondly, it was pointed out that this association enhances DOX cytotoxic effect on numerous cancer cell lines, such as prostate cancer, neuroblastoma, leukaemia, breast cancer, or CRC [20,[27][28][29][30].…”

Section: Introductionmentioning

confidence: 99%

A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of liposomes co-encapsulating SIM and DOX, by implementing the Quality by Design (QbD) concept, as a means to enhance the antiproliferative effect of the co-formulation on C26 murine colon cancer cells co-cultured with macrophages. It is known that the quality profile of liposomes is dependent on the critical quality attributes (CQAs) of liposomes (drug entrapped concentration, encapsulation efficiency, size, zeta potential, and drug release profile), which are, in turn, directly influenced by various formulation factors and processing parameters. By using the design of experiments, it was possible to outline the increased variability of CQAs in relation to formulation factors and identify by means of statistical analysis the material attributes that are critical (phospholipids, DOX and SIM concentration) for the quality of the co-formulation. The in vitro studies performed on a murine colon cancer cell line highlighted the importance of delivering the optimal drug ratio at the target site, since the balance antiproliferative vs. pro-proliferative effects can easily be shifted when the molar ratio between DOX and SIM changes.

show abstract

“…The potency of these drugs is highly influenced by their physicochemical properties. Lipophilic statins, i.e ., simvastatin, mevastatin, lovastatin, and pitavastatin, can easily cross cell membranes by diffusion, while hydrophilic statins, i.e ., pravastatin, need special membrane transporters[ 12 , 15 , 17 , 18 ]. Another difference arises due to their molecular structure.…”

Section: Mechanism Of Action Of Statinsmentioning

confidence: 99%

“…These mechanisms were considered the basis for introducing statins in cancer treatment and prevention[ 8 , 11 ]. The antiproliferative effects of statins are a result of both inhibition of the mevalonate pathway and their pleiotropic effects, i.e ., antioxidant, anti-inflammatory and immune modulatory properties, with a major impact on patient survival and cancer recurrence[ 10 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Statins in risk-reduction and treatment of cancer

Barbălată

Tefas

Achim

et al. 2020

WJCO

View full text Add to dashboard Cite

Statins, which are competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, reduce cholesterol blood levels and the risk of developing cardiovascular diseases and their related complications. In addition to this main activity, statins show pleiotropic effects such as antioxidant, anti-inflammatory and antiproliferative properties, with applications in many pathologies. Based on their antiproliferative properties, in vitro and in vivo studies have investigated their effects on various types of cancer ( i.e ., breast cancer, prostate cancer, colorectal cancer, ovarian cancer, lung cancer) with different genetic and molecular characteristics. Many positive results were obtained, but they were highly dependent on the physiochemical properties of the statins, their dose and treatment period. Combined therapies of statins and cytotoxic drugs have also been tested, and synergistic or additive effects were observed. Moreover, observational studies performed on patients who used statins for different pathologies, revealed that statins reduced the risk of developing various cancers, and improved the outcomes for cancer patients. Currently, there are many ongoing clinical trials aimed at exploring the potential of statins to lower the mortality and the disease-recurrence risk. All these results are the foundation of new treatment directions in cancer therapy.

show abstract

Association between statin use and all-cause mortality in cancer survivors, based on the Korean health insurance service between 2002 and 2015

Cited by 8 publications

References 21 publications

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy

Statins in risk-reduction and treatment of cancer

Contact Info

Product

Resources

About